Loading...
Loading...
In a report published Monday, H.C. Wainwright & Co. analyst Reni Benjamin initiated coverage on
Spectrum PharmaceuticalsSPPI with a Buy rating and $15.00 price target.
In the report, H.C. Wainwright & Co. noted, “We are initiating coverage of Spectrum Pharmaceuticals with a BUY rating and a target price of $15, based on a discounted revenues and earnings per share valuation methodology. Spectrum Pharmaceuticals future value is supported by the revenue generated from four marketed products: Fusilev, Zevalin, Folotyn, and Marqibo. Combined, annual revenues should reach $165 MM by 2014, and continue growing at a 5-10% growth rate, in our opinion. The company also has a late-stage clinical development program comprised of belinostat for PTCL, apaziquone for bladder cancer, and a captisol-enabled melphalan for autologous stem cell transplants, as well as a pipeline of earlier stage products to fuel growth. With a solid portfolio of diverse oncology assets, and a strong cash position of $128 MM, we believe Spectrum represents an undervalued player with significant upside for the long-term investor.”
Spectrum Pharmaceuticals closed on Friday at $8.49.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in